Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 3;11(6):e4813.
doi: 10.7759/cureus.4813.

Pros and Cons of Marijuana in Treatment of Parkinson's Disease

Rikinkumar S Patel  1 , Saher Kamil  2 , Mansi R Shah  3 , Narmada Neerja Bhimanadham  4 , Sundus Imran  5
Affiliations
Review

Pros and Cons of Marijuana in Treatment of Parkinson's Disease

Rikinkumar S Patel et al. Cureus. .

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder of adult onset in the United States. It is a debilitating condition and presents with both motor and non-motor symptoms. Current treatment options are scarce and include replacement of dopamine deficiency with levodopa which targets only motor symptoms of the disorder, does not halt its progression, and is associated with side effects of its own, including dyskinesia. With medical marijuana gaining popularity and being legalized in the United States, we examined the pros and cons of marijuana in the treatment of Parkinson's disease.

Keywords: marijuana; medical marijuana; parkinson; parkinson disease.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Epidemiology of Parkinson's disease. Tysnes OB, Storstein A. J Neural Transm (Vienna) 2017;124:901–905. - PubMed
    1. Marijuana compounds: a nonconventional approach to parkinson's disease therapy. Babayeva M, Assefa H, Basu P, Chumki S, Loewy Z. Parkinsons Dis. 2016;2016:1279042. - PMC - PubMed
    1. Pros and cons of medical cannabis use by people with chronic brain disorders. Suryadevara U, Bruijnzeel DM, Nuthi M, Jagnarine DA, Tandon R, Bruijnzeel AW. Curr Neuropharmacol. 2017;15:800–814. - PMC - PubMed
    1. Cannabis use in people with Parkinson's disease and multiple sclerosis: a web-based investigation. Kindred JH, Li K, Ketelhut NB, et al. Complement Ther Med. 2017;33:99–104. - PubMed
    1. Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. Bisogno T, Di Marzo V. CNS Neurol Disord Drug Targets. 2010;9:564–573. - PubMed

LinkOut - more resources